Trial Profile

PIONEER: A Phase I Study of Olaparib in Combination with Chemo-radiation in Locally Advanced Pancreatic Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Capecitabine
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Adverse reactions
Acronyms PIONEER

Most Recent Events

03 Aug 2022 Status changed from suspended to completed.
01 May 2020 Status changed to suspended.
08 Apr 2020 Planned End Date changed from 30 Apr 2019 to 31 Jul 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com